Skip to main content

Table 5 Treatment emergent adverse events (TEAEs)

From: Antiviral treatment perspective against Borna disease virus 1 infection in major depression: a double-blind placebo-controlled randomized clinical trial

Patients N = 32Differences A vs. PPatients with Amantadine (A) N = 33aPatients with Placebo (P) N = 33a
Side effects 1511
No side effects 1822
Side effect rate (%)Non-significant difference15/33 = 0.454 (45.4%)11/32 = 0.333 (33.3%)
Absolute side effect difference45.4–33.3% = 12.1%  
Relative risk (RR)45.4/33.3 = 1.363  
Odds 15/18 = 0.8311/22 = 0.50
Odds ratio (OR)0.83/0.5 = 1.66  
  1. aTwo of the 33 patients did not participate/finish the second treatment period. Time endpoint: 14 weeks, 6 weeks amantadine, 1 week off, 6 weeks placebo, and cross - over treatment